Stinging insect hypersensitivity: A practice parameter update 2011

详细信息    查看全文

• 作者：David B.K. Golden MD ; Chief Editor ; John Moffitt MD ; Chief Editor ; Richard A. Nicklas MD ; Chief Editor ; Theodore Freeman MD ; Workgroup Contributor ; David F. Graft MD ; Workgroup Contributor ; Robert E. Reisman MD ; Workgroup Contributor ; James M. Tracy DO ; Workgroup Contributor ; David Bernstein MD ; Task Force Reviewer ; Joann Blessing-Moore MD ; Task Force Reviewer ; Linda Cox MD ; Task Force Reviewer ; David A. Khan MD ; Task Force Reviewer ; David M. Lang MD ; Task Force Reviewer ; John Oppenheimer MD ; Task Force Reviewer ; Jay M. Portnoy MD ; Task Force Reviewer ; Christopher Randolph MD ; Task Force Reviewer ; Diane E. Schuller MD ; Task Force Reviewer ; Sheldon L. Spector MD ; Task Force Reviewer ; Steven A. Tilles MD ; Task Force Reviewer ; Dana Wallace MD ; Task Force Reviewer
• 关键词：Insect hypersensitivity ; anaphylaxis
• 刊名：Journal of Allergy and Clinical Immunology
• 出版年：2011
• 出版时间：April 2011
• 年：2011
• 卷：127
• 期：4
• 页码：852-854.e23
• 全文大小：1109 K

文摘

These parameters were developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma and Immunology.

The AAAAI and the ACAAI have jointly accepted responsibility for establishing “Stinging insect hypersensitivity: a practice parameter update II.” Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task Force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or the ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma and Immunology. This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. These parameters are not designed for use by pharmaceutical companies in drug promotion. The Joint Task Force understands that the cost of diagnostic tests and therapeutic agents is an important concern that may appropriately influence the work-up and treatment chosen for a given patient. The Joint Task Force recognizes that the emphasis of our primary recommendations regarding a medication may vary, for example, depending on third party payer issues and product patent expiration dates. However, since a given test or agent's cost is so widely variable, and there is a paucity of pharmacoeconomic data, the Joint Task Force generally does not consider cost when formulating Practice Parameter recommendations. In extraordinary circumstances, when the cost benefit of an intervention is prohibitive as supported by pharmacoeconomic data, commentary may be provided.